Centessa Pharmaceuticals Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 129

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $7.8B

  • Investors
  • 1

Centessa Pharmaceuticals General Information

Description

Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.

Contact Information

Formerly Known As
United Medicines Biopharma
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 3rd Floor 1 Ashley Road
  • Cheshire
  • Altrincham WA14 2DT
  • England, United Kingdom
+44 026
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 3rd Floor 1 Ashley Road
  • Cheshire
  • Altrincham WA14 2DT
  • England, United Kingdom
+44 026

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Centessa Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 24-Jun-2026 $7.8B Completed Generating Revenue
6. 2PO 14-Nov-2025 Completed Generating Revenue
5. Debt Refinancing 30-Dec-2024 Completed Generating Revenue
4. 2PO 13-Sep-2024 Completed Generating Revenue
3. 2PO 25-Apr-2024 Completed Generating Revenue
2. IPO 28-May-2021 $330M $552M Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 29-Jan-2021 $222M $222M Completed Clinical Trials - General
To view Centessa Pharmaceuticals’s complete valuation and funding history, request access »

Centessa Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-
Drug Discovery
Altrincham, United Kingdom
129 As of 2026

South San Francisco, CA
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Centessa Pharmaceuticals Competitors (7)

One of Centessa Pharmaceuticals’s 7 competitors is ORIC Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ORIC Pharmaceuticals Formerly VC-backed South San Francisco, CA
BridgeBio Pharma Formerly VC-backed Palo Alto, CA
Black Diamond Therapeutics Formerly VC-backed Cambridge, MA
Cullinan Therapeutics Formerly VC-backed Cambridge, MA
Roivant Sciences Formerly PE-Backed New York, NY
You’re viewing 5 of 7 competitors. Get the full list »

Centessa Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Centessa Pharmaceuticals Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Oberland Capital PE/Buyout Minority
To view Centessa Pharmaceuticals’s complete investors history, request access »

Centessa Pharmaceuticals Acquisitions (10)

Centessa Pharmaceuticals’s most recent deal was a Merger/Acquisition with Morphogen-IX. The deal was made on 23-Feb-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Morphogen-IX 23-Feb-2021 Merger/Acquisition Drug Discovery
Capella BioScience 16-Feb-2021 Merger/Acquisition Drug Discovery
Inexia 16-Feb-2021 Merger/Acquisition Drug Discovery
Orexia 16-Feb-2021 Merger/Acquisition Drug Discovery
PearlRiver Bio 16-Feb-2021 Merger/Acquisition Drug Discovery
You’re viewing 5 of 10 acquisitions. Get the full list »

Centessa Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated April, 30, 2023

34.66 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,669

Rank

Percentile

Pharmaceuticals

Industry

of 895

Rank

Percentile

Pharmaceuticals

Subindustry

of 431

Rank

Percentile

To view Centessa Pharmaceuticals’s complete esg history, request access »

Centessa Pharmaceuticals Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Inexia London, United Kingdom 2018
Orexia London, United Kingdom 2018
Morphogen-IX Cambridge, United Kingdom 2015
Z Factor Cambridge, United Kingdom 2015
Capella BioScience London, United Kingdom 2014

Centessa Pharmaceuticals FAQs

  • When was Centessa Pharmaceuticals founded?

    Centessa Pharmaceuticals was founded in 2019.

  • Where is Centessa Pharmaceuticals headquartered?

    Centessa Pharmaceuticals is headquartered in Altrincham, United Kingdom.

  • What is the size of Centessa Pharmaceuticals?

    Centessa Pharmaceuticals has 129 total employees.

  • What industry is Centessa Pharmaceuticals in?

    Centessa Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Centessa Pharmaceuticals a private or public company?

    Centessa Pharmaceuticals is a Private company.

  • What is the current valuation of Centessa Pharmaceuticals?

    The current valuation of Centessa Pharmaceuticals is .

  • What is Centessa Pharmaceuticals’s current revenue?

    The current revenue for Centessa Pharmaceuticals is .

  • How much funding has Centessa Pharmaceuticals raised over time?

    Centessa Pharmaceuticals has raised $1.36B.

  • Who are Centessa Pharmaceuticals’s investors?

    Oberland Capital has invested in Centessa Pharmaceuticals.

  • Who are Centessa Pharmaceuticals’s competitors?

    ORIC Pharmaceuticals, BridgeBio Pharma, Black Diamond Therapeutics, Cullinan Therapeutics, and Roivant Sciences are some of the 7 competitors of Centessa Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process